Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy,Arthritis & Rheumatology

当前位置： X-MOL 学术 › Arthritis Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy
Arthritis & Rheumatology ( IF 13.3 ) Pub Date : 2024-04-01 , DOI: 10.1002/art.42850
Kate Gregory _{1,

2} , Dylan Hansen ₃ , Ross Penglase _{4,

5,

6} , Diane Apostolopoulos _{1,

2} , Gene‐Siew Ngian _{1,

2} , Wendy Stevens ₃ , Kathleen Morrisroe _{3,

7,

8} , Nava Ferdowsi ₃ , Laura Ross _{3,

8} , Jennifer Walker ₉ , Helen Cooley ₁₀ , Peter Youssef ₁₁ , Kathleen Tymms ₇ , Lauren Host ₁₂ , Susanna Proudman _{9,

13} , John Moore _{4,

5,

6} , Mandana Nikpour _{3,

8} , Joanne Sahhar _{1,

2}

Affiliation

The study objective was to determine the event-free survival (EFS) of Australian patients with diffuse cutaneous systemic sclerosis (dcSSc) who met eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomized controlled trials but were not treated with ASCT.

中文翻译：